China Universal Asset Management Co. Ltd. Raises Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

China Universal Asset Management Co. Ltd. grew its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 10.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 147,754 shares of the company’s stock after buying an additional 13,788 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in ImmunityBio were worth $378,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. State Street Corp boosted its holdings in ImmunityBio by 10.1% in the third quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of ImmunityBio by 2.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company’s stock worth $4,709,000 after buying an additional 29,665 shares during the last quarter. Barclays PLC grew its holdings in shares of ImmunityBio by 127.4% in the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after acquiring an additional 202,248 shares during the period. GSA Capital Partners LLP increased its position in ImmunityBio by 290.3% during the third quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock valued at $402,000 after acquiring an additional 80,318 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in ImmunityBio by 15.6% in the second quarter. The Manufacturers Life Insurance Company now owns 94,367 shares of the company’s stock valued at $596,000 after acquiring an additional 12,738 shares during the period. 8.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on IBRX shares. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research report on Monday, January 27th. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. Finally, BTIG Research initiated coverage on ImmunityBio in a research note on Friday, January 10th. They issued a “buy” rating and a $6.00 price objective for the company.

ImmunityBio Trading Down 0.6 %

NASDAQ IBRX opened at $3.45 on Monday. ImmunityBio, Inc. has a 12 month low of $2.28 and a 12 month high of $10.53. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -3.75 and a beta of 0.86. The company’s 50 day moving average is $3.33 and its two-hundred day moving average is $3.97.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.